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and 11%, respectively; p = 0.066). Multivariate analysis re-
vealed renal failure (odds ratio [OR] = 4.9, 95% confidence 
interval [CI] = 1.8–13.0), treatment with OH (OR = 3.3, 95%
CI = 1.2–9.0), peripheral vascular surgery (OR = 2.7, 95%
CI = 1.2–6.0), and prior diuretic therapy (OR = 2.6, 95% CI = 
1.1–5.7) being independently associated with 2-year all-
cause death. No difference existed in postoperative isch-
emia among the different groups.  Conclusions: Long-term 
mortality after major non-cardiac surgery is elevated in pa-
tients with CAD and diabetes mellitus only if they are treated 
with OH, but not if they are treated with insulin. Further eval-
uation of the impact of perioperative anti-diabetic treat-
ment on morbidity and mortality in CAD is warranted. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Type 2 diabetes mellitus (DM) is a significant health 
problem worldwide, affecting 4–6% of the population  [1, 
2] . While DM is an important risk factor for the develop-
ment of coronary artery disease (CAD)  [3] , the outcome 
of CAD is poorer in patients with DM than in those with-
out DM  [4, 5] .
 While tight perioperative metabolic control improves 
postoperative outcome  [6, 7] , the influence of the type of 
preoperative hypoglycemic therapy on outcome in pa-
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 Abstract 
 Background: Diabetes mellitus (DM), particularly if insulin-
dependent, is a predictor of increased perioperative risk, 
whereas stringent metabolic control with insulin is benefi-
cial in the critically ill.  Methods: The impact of oral hypogly-
cemics (OH) vs. insulin on outcome was determined as a sec-
ondary retrospective analysis of a cohort study in patients 
with coronary artery disease (CAD) and DM undergoing ma-
jor non-cardiac surgery. Primary end-point was 2-year all-
cause mortality; secondary endpoints were perioperative 
myocardial ischemia and 2-year cardiac mortality.  Results: 
Of 173 patients, DM was diagnosed in 42 (24%) based on pre-
existing treatment with OH (15%) or insulin (9%). During fol-
low-up, 40/173 (23%) patients died. All-cause mortality was 
similar in the non-diabetic (20%) and insulin groups (19%) 
but significantly higher in the OH group (42%; p = 0.025). 
Cardiac mortality tended to be higher in the OH group com-
pared with the insulin and non-diabetic groups (27 vs. 19% 
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tients with DM and known or suspected CAD undergo-
ing non-cardiac surgery is not known. Insulin treatment 
is an independent predictor of cardiac risk after major 
non-cardiac surgery  [8] . Consequently, current guide-
lines for perioperative cardiovascular evaluation describe 
DM as a predictor of risk for cardiac complications par-
ticularly if insulin-treated  [9] . Nevertheless, the effects of 
oral hypoglycemics (OH) on perioperative outcome have 
not been sufficiently evaluated. This is surprising as there 
are conflicting results concerning cardiovascular mor-
tality in non-surgical patients with and without docu-
mented CAD treated with OH  [4, 10–14] . In contrast, in-
sulin treatment combined with a strict blood glucose 
control reduces mortality in critically ill patients  [7] and 
in patients with acute myocardial infarction  [15–17] . 
However, mortality from myocardial infarction was not 
decreased when glucose levels failed to be lowered by in-
tense insulin therapy  [18] . The aim of this analysis was to 
determine the impact of DM and its treatment strategy 
(OH vs. insulin) on long-term outcome in patients with 
documented or highly suspected CAD undergoing major 
non-cardiac surgery.
 Materials and Methods 
 Subjects and Definitions 
 This is a secondary analysis of a prospective observational co-
hort study of preoperative risk stratification in patients with or at 
risk for CAD  [19, 20] . The local institutional review board ap-
proved the study protocol, and each of the patients gave informed 
written consent. In brief, patients were eligible if they had known 
or suspected CAD, and were scheduled for major non-cardiac sur-
gery defined as abdominal aortic surgery, peripheral vascular sur-
gery of the lower limb, laparotomy, major orthopedic surgery, 
thoracotomy, and major surgery of the neck. CAD was considered 
as documented if patients had myocardial ischemia in dobuta-
mine stress echocardiography or dipyridamole thallium imaging, 
significant stenoses in a previous coronary angiography, a prior 
myocardial infarction, or prior myocardial revascularization; 
CAD was considered as suspected if patients had typical angina 
or if vascular surgery was planned and  6 2 of the following crite-
ria were present: age  1 70 years, hypertension, DM, prior stroke, 
impaired exercise tolerance, or a pathologic resting ECG. DM was 
diagnosed if patients were treated with insulin or OH at admis-
sion; some of the patients may have been diabetic based on their 
blood glucose levels, but were analyzed as non-diabetics due to 
lacking drug treatment. Renal failure was defined as a calculated 
creatinine clearance of  ! 30 ml/min.
 Methods 
 Continuous ECG recording (Marquette Series 8500, Mar-
quette Electronics, Milwaukee, Wisc., USA) was started before 
induction of anesthesia and continued for 48 h, and ST segment 
depressions of  6 2 mm  6 1 min were considered as significant. 
Cardiac troponin I was measured on the first and second day after 
surgery using a commercially available kit (AxSYM  , Abbott, Ab-
bott Park, Ill., USA) with the normal upper limit of 2   g/l speci-
fied by the manufacturer. Glucose levels were assessed preopera-
tively in all patients in a fasting state, but postoperatively only in 
diabetic patients using enzymatic methods (Roche Diagnostics, 
Basel, Switzerland). Interventions for establishing perioperative 
metabolic control were not pre-specified and left to the discretion 
of the physicians in charge.
 Endpoints and Follow-Up 
 The primary endpoint was all-cause mortality after 2 years; 
secondary endpoints were cardiac mortality after 2 years, and ev-
idence of perioperative myocardial ischemia (cardiac troponin I 
 1 2   g/l and ST segment depressions  6 2 mm  6 1 min in the first 
2 days after surgery). Semistructured follow-up interviews were 
performed by telephone at 6, 12, and 24 months after surgery. 
Cause of death was obtained from the Swiss Mortality Registry 
(Federal Statistical Office, Bern, Switzerland).
 Statistical Analysis 
 Statistical analysis was performed using Stat View  software 
version 5.0.1 (SAS Institute Inc., Cary, N.C., USA). Continuous 
data were analyzed using the Mann-Whitney U and Kruskal-
Wallis tests, and categorical data using Fisher’s exact and    2  tests, 
where appropriate. All continuous data were expressed as median 
values with their range. Multivariate analysis using logistic re-
gression was done considering baseline variables with an initial
p  ! 0.05. Single variables were removed in a stepwise method un-
til the model met a 0.05 significance level in all variables. Sur-
vival was compared using Kaplan-Meier survival curves and log-
rank test. P  values were two-sided and considered to indicate sta-
tistical significance if  ! 0.05.
 Results 
 DM was diagnosed in 42 (24%) patients from whom 
26 (15%) were chronically treated with OH (OH group) 
and 16 (9%) with insulin only (insulin group). In the OH 
group, 17 patients received sulfonylureas, 2 metformin, 
and 1 repaglinide as only OH drug. Six patients received 
a combination of sulfonylureas and metformin. Three 
patients treated with OH and insulin were analyzed as 
part of the OH group. Baseline characteristics are shown 
in  table 1 . Levels of HbA 1c  tended to be higher in patients 
treated with insulin, but were similar in patients with DM 
treated with OH and non-diabetic patients. Patients with-
out DM had lower preoperative blood glucose levels than 
patients with DM, but glucose levels differed neither be-
fore nor after surgery in the two DM groups. No differ-
ence existed in postoperative ischemia among the differ-
ent groups ( table 2 ). All-cause mortality tended to be 
higher in diabetic than in non-diabetic patients (33 vs. 
20%, p = 0.059), and was similar in insulin-treated (19%) 
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and non-diabetic patients but significantly higher in pa-
tients with OH (42%; p = 0.025;  fig. 1 ). Cardiac mortality 
was higher in diabetic than in non-diabetic patients (24 
vs. 11%, p = 0.037), and tended to be higher in the OH 
group (27%) than in the insulin group (19%) and in non-
diabetic patients (p = 0.066). In univariate analysis pre-
dictors of death were age  1 70 years, hypertension, renal 
failure, history of congestive heart failure, treatment with 
OH and diuretics, aortic surgery, and peripheral vascular 
surgery. Independent predictors of death were renal fail-
ure, peripheral vascular surgery, and treatment with OH 
and diuretics ( table 3 ).
Table 1. Baseline characteristics
All
(n = 173)
No DM
(n = 131)
OH
(n = 26)
Insulin
(n = 16)
p*
Age, years 73 (47–89) 73 (47–89) 75 (52–84) 72 (50–77) 0.29
Female 33 31 31 56 0.11
Body mass index, kg/m2 25 (14–38) 25 (14–37) 26 (21–33) 28 (19–38) 0.24
Creatinine clearance, ml/min 70 (5–176) 67 (5–176) 73 (16–144) 77 (9–133) 0.71
Renal failure 15 16 8 19 0.50
Hypertension 69 66 65 81 0.17
Current smoking 25 39 19 13 0.29
Hypercholesterolemia (n = 167) 57 60 58 50 0.86
Angina pectoris 31 33 24 31 0.62
Shortness of breath 60 61 50 62 0.56
History of myocardial infarction 51 55 50 19 0.02
Prior revascularization 29 34 31 6 0.03
History of congestive heart failure 13 11 23 19 0.19
Ongoing malignant disease 25 27 19 13 0.33
Drug therapy
Acetylic salicylic acid 59 61 50 56 0.56
Coumadin 19 15 35 25 0.06
Diuretics 37 36 46 50 0.25
Inhibitors of ACE 35 32 46 44 0.29
Beta-blockers 34 38 15 31 0.08
Ca-antagonists 27 26 27 31 0.90
Long-acting nitrates 20 18 23 25 0.73
Digoxin 8 8 15 0 0.19
Amiodarone 5 6 0 6 0.43
Surgery
ASA classification 0.56
ASA II 9 11 4 0
ASA III 81 79 84 88
ASA IV 10 10 12 12
Emergency surgery 2 2 4 0 0.72
Abdominal aortic surgery 34 37 35 6 0.046
Peripheral vascular surgery of the lower limb 32 24 46 69 0.0004
Laparotomy 23 27 8 13 0.06
Major orthopedic surgery 8 8 8 13 0.79
Thoracotomy 2 3 0 0 0.52
Major surgery of the neck 1 1 4 0 0.37
Values are median values with range or % of patients.
* Kruskal-Wallis test for continuous, 2 test for categorical variables.
ACE = Angiotensin-converting enzyme; ASA = American Society of Anesthesiologists; CrCl = creatinine 
clearance; DM = diabetes mellitus; OH = oral hypoglycemics.
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Table 2. Perioperative management, metabolic control, and ischemia
All No DM OH Insulin p*
(n = 173) (n = 131) (n = 26) (n = 16)
Perioperative hypoglycemic therapy, %
Intraoperative insulin – – 14 58 0.016
Postoperative insulin – – 19 62 0.025
Insulin 1st day after surgery – – 19 92 <0.0001
Insulin 2nd day after surgery – – 29 92 0.0004
Insulin 3rd day after surgery – – 14 92 <0.0001
Insulin at discharge – – 15 100 <0.0001
OH 1st day after surgery – – 33 0 0.029
OH 2nd day after surgery – – 48 0 0.0049
OH 3rd day after surgery – – 52 0 0.0018
OH at discharge – – 80 0 <0.0001
Perioperative metabolic control, % and mmol/l, respectively
HbA1c (n = 15) 7.3 (5.1–10.2) 6.6 (5.9–7.9) 6.7 (5.1–8.8) 8.5 (6.4–10.2) 0.087
Glucose day before surgery 6.3 (3.6–16.5) 6.2 (3.9–14.0) 7.8 (3.6–14.6) 7.9 (6.2–16.5) 0.0002
Glucose 1st day after surgery – – 7.8 (5.0–12.5) 9.6 (5.4–22.8) 0.22
Glucose 2nd day after surgery – – 8.1 (4.6–12.3) 8.2 (4.4–20.1) 0.45
Glucose 3rd day after surgery – – 7.9 (4.5–12.0) 7.6 (3.9–15.8) 0.88
Postoperative ischemia (days 1 and 2), %
Elevated cardiac troponin I 16 15 25 15 0.55
ST depressions (n = 117) 46 42 50 63 0.24
Values are median values with range or % of patients.
* Mann-Whitney U test and Kruskal-Wallis test for continuous, Fisher’s test, and 2 test for categorical vari-
ables, where appropriate. DM = Diabetes mellitus; OH = oral hypoglycemics.
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 Fig. 1. Kaplan-Meier survival curves for patients without DM and 
for patients with DM treated with insulin and OH, respectively 
(p = 0.025, log-rank test). 
Table 3. Multivariate predictors of 2-year all-cause mortality
OR 95% CI 2 p
Renal failure 4.9 1.8–13.0 10.2 0.0014
Oral hypoglycemic treatment 3.3 1.2–9.0 5.3 0.021
Peripheral vascular surgery 2.7 1.2–6.0 5.6 0.018
Diuretic treatment 2.6 1.1–5.7 5.2 0.022
CI = Confidence interval; OR = odds ratio.
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 Discussion 
 This study performed in diabetic patients with docu-
mented or suspected CAD undergoing major non-car-
diac surgery found that treatment with OH was an inde-
pendent predictor of 2-year all-cause mortality. In con-
trast, patients treated with insulin had the same outcome 
as patients without DM. This finding was unexpected as 
current guidelines and risk indices consider DM as a risk 
factor particularly if treated with insulin. Previous data 
show that tight metabolic control, as reflected by nor-
moglycemia, in both diabetic and non-diabetic patients 
with critical diseases, was related to beneficial outcome 
 [18, 21] . Our data do not provide an explanation for this 
finding, which could reflect either a beneficial effect of 
insulin or a detrimental effect of OH. Potential benefi-
cial effects of insulin are better metabolic control, anti-
inflammatory and anti-atherogenic effects, and benefi-
cial effects on intracellular mechanisms in the ischemic 
myocardium  [22, 23] . However, metabolic glucose con-
trol in the insulin group was not better than in the OH 
group, as could have been expected. In addition, up to 
50% of the patients in the OH group received insulin 
during and early after surgery and, thus, were at least 
partially exposed to the potential beneficial effects of 
insulin. Thus, it is unlikely that our findings can be ex-
plained by the beneficial effects of insulin but might re-
flect potentially deleterious effects of OH as adminis-
tered before surgery. Sulfonylureas prevent ischemic 
preconditioning by inhibiting cardiac KATP-channels 
 [24] . As perioperative myocardial ischemia is common 
in CAD patients and associated with unfavorable out-
come  [20, 25] , one can hypothesize that this inhibition 
prior to surgery might have caused the observed differ-
ence in mortality rates post surgery. However, not con-
sistent with this hypothesis, were the similar incidences 
of perioperative myocardial ischemia (i.e., elevation of 
cardiac troponin I and ST segment depression) in all 
study groups. This latter finding and the lack of statisti-
cally significant differences in  cardiac mortality among 
the study groups suggest that the higher all-cause mor-
tality in OH treated patients might have been caused 
only partially by cardiac side effects. The multivariate 
analysis revealed renal failure, treatment with diuretics, 
and peripheral vascular surgery as additional indepen-
dent predictors of 2-year all-cause mortality. Both renal 
failure  [8] and peripheral vascular surgery  [26] are 
known risk factors for perioperative mortality, while 
preoperative treatment with diuretics might be a surro-
gate for underlying hypertension and congestive heart 
failure, which were both associated with adverse out-
come in the univariate analysis.
 Our study has several limitations. First, it was a sec-
ondary analysis of prospectively collected data. Second, 
the number of patients with DM was too small to allow 
for final conclusions and data on the duration of DM and 
late diabetic complications were missing. Nevertheless, 
the study was large enough to clearly identify OH-treated 
DM as an independent predictor of all-cause mortality in 
our cohort, and it is unlikely that this result happened by 
chance. Third, the study groups were not identical re-
garding patient characteristics. However, the higher rate 
of peripheral vascular surgery and the lower rate of prior 
myocardial infarction with revascularization in the insu-
lin group would have been more consistent with a higher 
and not a lower mortality, because mortality in periph-
eral vascular surgery is expected to be the highest  [9, 27] 
and prior revascularization might provide a better post-
operative survival  [9, 28] .
 Conclusion 
 In conclusion, our study indicates that chronic treat-
ment with OH but not with insulin was associated with 
elevated long-term mortality in diabetic CAD patients af-
ter major non-cardiac surgery. This finding might have 
been caused by either a beneficial effect of insulin per se, 
or a detrimental effect of OH during and after surgery. 
Due to the nature of our analysis and the limitations of 
our study, our data is hypothesis-generating rather than 
hypothesis-proving. Because of the high numbers of OH-
treated patients that undergo non-cardiac surgery and 
the potentially high impact on outcome, our findings 
identify an urgent need for additional prospective trials 
to clarify the optimal perioperative treatment strategy in 
patients with DM. Meanwhile, OH-treated DM should be 
considered as an equivalent risk factor for adverse out-
come as insulin-treated DM.
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